Zobrazeno 1 - 10 of 48 pro vyhledávání: '"Tatsuo Yanagawa"'
1
Akademický článek
A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis
Autor: Miyu Kinoshita, Koichiro Azuma, Tatsuo Yanagawa
Publikováno v: Journal of Clinical and Translational Endocrinology Case Reports, Vol 25, Iss , Pp 100124- (2022)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus are gaining popularity due to their cardioprotective and renoprotective effects, yet SGLT2 inhibitors are increasingly associated with euglycemic diabetic
Externí odkaz: https://doaj.org/article/ebf689e807264cec9378be1d90849f2f
Zobrazit plný text záznamu
3
Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression
Autor: Tatsuo Yanagawa, Keiko Koyano, Koichiro Azuma
Publikováno v: Diabetol Int
AIM: This study was aimed at retrospectively investigating some common clinical factors, including the serum level of magnesium (Mg), associated with progression and remission/regression of diabetic kidney disease (DKD). METHODS: The subjects were 69
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7159c64594e97fca60c53be54bcb27
https://pubmed.ncbi.nlm.nih.gov/34150435
Zobrazit plný text záznamu
4
Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with Sodium-Glucose Cotransporter 2 Inhibitors
Autor: Keiko Koyano, Shuhei Iida, Yasuhiro Sasaki, Tatsuo Yanagawa
Publikováno v: Journal of Diabetes Mellitus. :241-248
Aim: The EMPA-REG OUTCOME study reported that the sodium-glucose cotransporter 2 inhibitor (SGLT2-i) suppressed cardiovascular (CV) events in patients with type 2 diabetes; we recently suggested that increase of the serum magnesium (Mg) by SGLT2-i’
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27d3d4181c629fb170129bcd92291e90
https://doi.org/10.4236/jdm.2017.74019
Zobrazit plný text záznamu
5
Is the Renoprotective Effect of SGLT2 Inhibitors due to their Beneficial Effect on Hypomagnesemia?
Autor: Tatsuo Yanagawa
Publikováno v: Journal of Diabetes & Metabolism. 8
Magnesium (Mg) deficiency is linked to diabetes and cardiovascular (CV) events. Treatment with the sodiumglucose cotransporter 2 (SGLT2) inhibitor was associated with a suppressed occurrence of CV events in patients with type 2 diabetes. We recently
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3b2785137f054cdab7bc81413a84559
https://doi.org/10.4172/2155-6156.1000772
Zobrazit plný text záznamu
6
Risk Factors for Pseudoaldosteronism with Rhabdomyolysis Caused by Consumption of Drugs Containing Licorice and Differences Between Incidence of These Conditions in Japan and Other Countries: Case Report and Literature Review
Autor: Tetsuhiro Yoshino, Kenji Watanabe, Tatsuo Yanagawa
Publikováno v: The Journal of Alternative and Complementary Medicine. 20:516-520
The pathogenesis of licorice-induced pseudoaldosteronism is thought to involve the inhibition of 11β-hydroxysteroid dehydrogenase type 2 by glycyrrhetinic acid. Some risk factors have been reported, but differences between Japan and other countries
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc0c096bdd1173ca8d445b8c38bc4167
https://doi.org/10.1089/acm.2013.0454
Zobrazit plný text záznamu
8
Albuminuria and left ventricular mass index are associated with left ventricular diastolic dysfunction in type 2 diabetes mellitus patients
Autor: Yoko Eto, Tatsuo Yanagawa, Yuko Kimura, Takateru Akiyama, Hideshi Matsuda
Publikováno v: Diabetology International. 5:129-133
Background Diabetes mellitus (DM) is associated with a substantially increased risk of developing heart failure. To verify the risk factors of preclinical left ventricular diastolic dysfunction (LVDD) in type 2 diabetic patients, we assessed the LVDD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0483df1da280478ebe2a133078b3cc8e
https://doi.org/10.1007/s13340-013-0146-7
Zobrazit plný text záznamu
9
Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)
Autor: Tatsuo Yanagawa, Choon Chung, Kyu Chang Won, Takayuki Watanabe, Minho Shong
Publikováno v: Diabetes, Obesity & Metabolism
Aims To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea. Methods In this 24-week, randomized, double-blind, placebo-controlled,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1951b333cb92a6f8fca5da537019e99c
https://doi.org/10.1111/j.1463-1326.2012.01618.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje